Information Provided By: 
Fly News Breaks for July 13, 2018
MYGN
Jul 13, 2018 | 15:59 EDT
Morgan Stanley analyst Steve Beuchaw, who upgraded Myriad Genetics to Overweight from Equal Weight on July 11, has issued a corrected version of the original upgrade note in order to adjust his price target on the stock to $47 from $55 based on modifications to his DCF valuation based on a revised way in which he considers amortization and a recent acquisition. Overall, he raised his FY19 and FY20 EPS estimates by 1% and 18%, respectively.
News For MYGN From the Last 2 Days
There are no results for your query MYGN
